23andMe (ME) Investor Presentation summary

Mission and business overview

• Aims to help people access, understand, and benefit from the human genome through two business verticals: consumer health and research partnerships.

• Offers personalized health, ancestry, telehealth, and recurring subscription services, leveraging a large, re-contactable genetic and phenotypic data engine.

• Over 15 million genotyped customers and 4.8 billion phenotypic data points, with more than 84% of customers opting into research.

• Provides direct-to-consumer genetic services, telehealth via Lemonaid Health, and a suite of health and ancestry products.

• Integrates AI and data partnerships to drive innovation and future growth.

Consumer health impact and engagement

• Genetics influences 8 of the top 10 causes of death in the US, with risk prediction and prevention shown to improve health outcomes.

• 76% of customers report taking positive health actions after learning about their genetics, such as eating healthier or exercising more.

• Over 28,000 customers identified with BRCA1/BRCA2 variants, 4 million with higher type 2 diabetes risk, and 2.2 million with increased coronary artery disease risk.

• Health Tracks tool demonstrates how lifestyle changes can reduce disease risk, supporting proactive, individualized care.

• High engagement: 84% US research consent rate, 12,000 daily research surveys, and 8.9 million customers logged in during 2024.

Product and service offerings

• Multiple genetic service tiers: Ancestry, Health + Ancestry, Premium, and Total Health, with reports on disease risk, carrier status, and pharmacogenetics.

• Telehealth services cover mental, men's, women's, and general health, with expanded access to GLP-1 drugs for weight management.

• FDA-authorized reports and actionable health insights, including personalized recommendations and medication guidance.

• Integration of EHR and claims data, wearable data, and lab results to enhance consumer features and research capabilities.